Consolidation hyperthermic intraperitoneal chemotherapy and maintenance chemotherapy following laparoscopic cytoreductive surgery in the treatment of ovarian carcinoma

Figures & data

Figure 1. (A) ThermaSolutions inflow/outflow tubing inserted into the abdominal cavity via the Alexis™ ring and base of the GelPort. (B). Placement of inflow/outflow tubing into the GelSeal™ cap.

Table 1. Demographic and pathological characteristics of the ovarian cancer patients treated with consolidation hyperthermic intraperitoneal carboplatin and paclitaxel maintenance chemotherapy (N = 37).

Demographic median	(range)
Age	63 years (45–83)
BMI*	25.2 kg/m^2 (17.4–48.6)
ECOG** performance status	0 (0–1)
	n (%)
Disease stage
IC	1 (2.7)
IIC	1 (2.7)
IIIA	2 (5.4)
IIIB	4 (10.8)
IIIC	25 (67.6)
IV	4 (10.8)
Grade
Poorly differentiated	26 (70.3)
Moderately differentiated	7 (18.9)
Well differentiated	4 (10.8)
Histology
Serous	24 (64.9)
Endometrioid	4 (10.8)
Mucinous	4 (10.8)
Mixed	2 (5.4)
Clear cell	2 (5.4)
Transitional cell	1 (2.7)

*Body mass index.

**Eastern cooperative oncology group.

Table 2. Toxicity profile for the ovarian cancer patients treated with consolidation hyperthermic intraperitoneal carboplatin and paclitaxel maintenance chemotherapy (N = 37).

	Carboplatin (AUC 10)
	Grade 1	Grade 2	Grade 3	Grade 4
Toxicity	n (%)	n (%)	n (%)	n (%)
Nausea	6 (16.2)	4 (10.8)	0 (0)	0 (0)
Emesis	2 (5.4)	1 (2.7)	0 (0)	0 (0)
Ileus	3 (8.1)	3 (8.1)	0 (0)	0 (0)
Anaemia	6 (16.2)	15 (40.5)	6 (16.2)	0 (0)
Neutropenia	6 (16.2)	8 (21.6)	0 (0)	0 (0)
Thrombocytopenia	5 (13.5)	5 (13.5)	0 (0)	0 (0)

Figure 2. Disease-free survival curve for the patients treated with consolidation hyperthermic intraperitoneal carboplatin chemotherapy and paclitaxel maintenance chemotherapy.

Figure 3. Overall survival curve for the patients treated with consolidation hyperthermic intraperitoneal carboplatin chemotherapy and paclitaxel maintenance chemotherapy.